



OIF E  
FEB 04 2002  
UNITED STATES PATENT AND TRADEMARK OFFICE

0300 / BOX 150g  
Page 1 of 1

2  
COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)

| APPLICATION NUMBER | FILING/RECEIPT DATE | FIRST NAMED APPLICANT | ATTORNEY DOCKET NUMBER |
|--------------------|---------------------|-----------------------|------------------------|
| 09/978,192         | 10/15/2001          | Avin Ashkenazi        | P2630P1C9              |

**CONFIRMATION NO. 3437**  
**FORMALITIES LETTER**

  
\*OC00000007167479\*

Ginger R. Dreger, Esq.  
Knobbe Martens Olson & Bear  
Suite 1150  
201 California Street  
San Francisco, CA 94111

Date Mailed: 12/07/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**


Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

**For questions regarding compliance to these requirements, please contact:**

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

  
Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



PATENT

Case Docket No. GNE.12630P1C9

Date: January 28, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Ashkenazi et al.


I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on

Appl. No. : 09/978,192

January 28, 2002

(Date)

Filed : October 15, 2001

  
Ginger R. Dreger, Reg. No. 33,055

For : SECRETED AND  
TRANSMEMBRANE  
POLYPEPTIDES AND  
NUCLEIC ACIDS  
ENCODING THE SAME

Examiner : Unknown

Group Art Unit : Unknown

TRANSMITTAL LETTER

COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231


Dear Sir:

Enclosed for filing in the above-identified application is the following:


- (X) Amendment;
- (X) Sequence Submission Statement;
- (X) Substitute Sequence Listing;
- (X) Substitute Sequence Listing in computer readable form;
- (X ) Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410; and

- (X) A return prepaid postcard.

  
Ginger R. Dreger  
Registration No. 33,055  
Attorney of Record

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Ashkenazi et al. ) Group Art Unit Unknown  
 Appl. No. : 10/978,192 )  
 Filed : October 15, 2001 ) I hereby certify that this correspondence and all  
 For : SECRETED AND ) marked attachments are being deposited with the  
 TRANSMEMBRANE ) United States Postal Service as first-class mail in  
 POLYPEPTIDES AND NUCLEIC ) an envelope addressed to: Commissioner for  
 ACIDS ENCODING THE SAME ) Patents, Washington, D.C. 20231, on  
 )  
 Examiner : Unknown ) January 28, 2002  
 ) (Date)  
  
 Ginger R. Dreger, Reg. No. 33,055

SEQUENCE SUBMISSION STATEMENT

Commissioner for Patents  
 Washington, D.C. 20231

Dear Sir:

This is in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed December 7, 2001. I hereby state that the amendments, made in accordance with 37 C.F.R. § 1.825(a) and included in the Substitute Sequence Listing submitted herewith, are supported in the application, and that the Substitute Sequence Listing does not include new matter.

I further state that the information recorded in the currently submitted substitute copy of the computer-readable form of the Sequence Listing is identical to the paper form of the Sequence Listing submitted herewith as required in 37 C.F.R. § 1.825(b).

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: January 28, 2002

By: Amy L.  
 Ginger R. Dreger  
 Registration No. 33,055  
 Attorney of Record  
 620 Newport Center Drive, 16<sup>th</sup> Floor  
 Newport Beach, CA 92660  
 (415) 954-4114